High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome after intensive treatment compared with de novo acute myeloid leukemia (AML) patients. This may reflect different disease-related and patient-related factors. The purpose of this analysis is to identify disease-specific prognostic factors and to develop prognostic scores for both patient groups. A total of 692 patients in the EORTC/GIMEMA AML-10 study and 289 patients in the CRIANT study received identical remission-induction and consolidation treatment. Estimated 5-year survival rate was 34 % in the AML-10 versus 27 % in the CRIANT study, and estimated disease-free survival was 40 % versus 28 %, respectively. In multivariate analysis, cytogenetic characteristics, white blood count, and age appeared prognostic for survival in both studies. French-American-British (FAB) subtype and performance status were prognostic in the AML-10 study only, whereas number of cytopenias and duration of antecedent hematologic disorder >6 months were prognostic in the CRIANT study only. The prognostic scores distinguish three groups with a 5-year survival rate of 54, 38, and 19 % in the AML-10 study versus 69, 37, and 5 % in the CRIANT study. The prognostic value of these scores has been validated on two external series. The new scoring systems form a practical tool to predict the outcome of individual MDS and AML patients treated with intensive antileukemic therapy.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies / Oosterveld, M; Suciu, S; Muus, P; Germing, U; Delforge, M; Belhabri, A; Aul, C; Selleslag, D; Ferrant, A; Marie, Jp; Amadori, S; Jehn, U; Mandelli, F; Hess, U; Hellström-Lindberg, E; Cakmak-Wollgast, S; Vignetti, M; Labar, B; Willemze, R; de Witte, T.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 94:1(2015), pp. 23-34. [10.1007/s00277-014-2177-y]

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

Amadori S;Mandelli F;Vignetti M;
2015

Abstract

High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome after intensive treatment compared with de novo acute myeloid leukemia (AML) patients. This may reflect different disease-related and patient-related factors. The purpose of this analysis is to identify disease-specific prognostic factors and to develop prognostic scores for both patient groups. A total of 692 patients in the EORTC/GIMEMA AML-10 study and 289 patients in the CRIANT study received identical remission-induction and consolidation treatment. Estimated 5-year survival rate was 34 % in the AML-10 versus 27 % in the CRIANT study, and estimated disease-free survival was 40 % versus 28 %, respectively. In multivariate analysis, cytogenetic characteristics, white blood count, and age appeared prognostic for survival in both studies. French-American-British (FAB) subtype and performance status were prognostic in the AML-10 study only, whereas number of cytopenias and duration of antecedent hematologic disorder >6 months were prognostic in the CRIANT study only. The prognostic scores distinguish three groups with a 5-year survival rate of 54, 38, and 19 % in the AML-10 study versus 69, 37, and 5 % in the CRIANT study. The prognostic value of these scores has been validated on two external series. The new scoring systems form a practical tool to predict the outcome of individual MDS and AML patients treated with intensive antileukemic therapy.
2015
De novo acute myeloid leukemia; High-risk myelodysplastic syndrome; Intensive antileukemic treatment; Prognostic scoring system; Secondary acute myeloid leukemia; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Europe; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Risk Factors; Survival Rate; Treatment Outcome; Young Adult; Severity of Illness Index; Hematology; Medicine (all)
01 Pubblicazione su rivista::01a Articolo in rivista
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies / Oosterveld, M; Suciu, S; Muus, P; Germing, U; Delforge, M; Belhabri, A; Aul, C; Selleslag, D; Ferrant, A; Marie, Jp; Amadori, S; Jehn, U; Mandelli, F; Hess, U; Hellström-Lindberg, E; Cakmak-Wollgast, S; Vignetti, M; Labar, B; Willemze, R; de Witte, T.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 94:1(2015), pp. 23-34. [10.1007/s00277-014-2177-y]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1189526
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact